JP2005531584A5 - - Google Patents

Download PDF

Info

Publication number
JP2005531584A5
JP2005531584A5 JP2004507477A JP2004507477A JP2005531584A5 JP 2005531584 A5 JP2005531584 A5 JP 2005531584A5 JP 2004507477 A JP2004507477 A JP 2004507477A JP 2004507477 A JP2004507477 A JP 2004507477A JP 2005531584 A5 JP2005531584 A5 JP 2005531584A5
Authority
JP
Japan
Prior art keywords
arthritis
disease
pharmaceutical composition
inflammatory
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004507477A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005531584A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/016072 external-priority patent/WO2003099820A1/en
Publication of JP2005531584A publication Critical patent/JP2005531584A/ja
Publication of JP2005531584A5 publication Critical patent/JP2005531584A5/ja
Withdrawn legal-status Critical Current

Links

JP2004507477A 2002-05-20 2003-05-16 ピラゾロピリミジンアニリン化合物 Withdrawn JP2005531584A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38201402P 2002-05-20 2002-05-20
PCT/US2003/016072 WO2003099820A1 (en) 2002-05-20 2003-05-16 Pyrazolo-pyrimidine aniline compounds

Publications (2)

Publication Number Publication Date
JP2005531584A JP2005531584A (ja) 2005-10-20
JP2005531584A5 true JP2005531584A5 (https=) 2006-06-01

Family

ID=29584346

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004507477A Withdrawn JP2005531584A (ja) 2002-05-20 2003-05-16 ピラゾロピリミジンアニリン化合物

Country Status (13)

Country Link
US (1) US6962915B2 (https=)
EP (1) EP1507780B1 (https=)
JP (1) JP2005531584A (https=)
AR (1) AR040031A1 (https=)
AU (1) AU2003241561A1 (https=)
ES (1) ES2391948T3 (https=)
IS (1) IS7534A (https=)
MY (1) MY135309A (https=)
NO (1) NO20044866L (https=)
PE (1) PE20040512A1 (https=)
PL (1) PL374218A1 (https=)
TW (1) TW200400034A (https=)
WO (1) WO2003099820A1 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
TW200306841A (en) 2002-04-23 2003-12-01 Bristol Myers Squibb Co Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
PT1497019E (pt) 2002-04-23 2015-09-10 Bristol Myers Squibb Co Compostos de pirrolotriazina anilina úteis como inibidores de quinase
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2003265349A1 (en) * 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
JP2006516653A (ja) 2003-02-05 2006-07-06 ブリストル−マイヤーズ　スクイブ　カンパニー キナーゼ阻害剤ピロロトリアジンの製造方法
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
AU2004309420B2 (en) * 2003-12-23 2008-10-30 Novartis Ag Bicyclic heterocyclic p-38 kinase inhibitors
RU2006134022A (ru) 2004-02-27 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные индазола и содержащие их фармацевтические композиции
WO2005085249A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
CN1934111A (zh) 2004-02-27 2007-03-21 霍夫曼-拉罗奇有限公司 杂芳基稠合的吡唑并衍生物
US7067659B2 (en) * 2004-04-23 2006-06-27 Duke University Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
TW200600513A (en) * 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7253167B2 (en) * 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
TW200618803A (en) 2004-08-12 2006-06-16 Bristol Myers Squibb Co Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
ES2368930T3 (es) 2004-09-06 2011-11-23 Bayer Pharma Aktiengesellschaft Pirazolopirimidinas como inhibidores de proteína cinasa b (akt).
GB0425035D0 (en) * 2004-11-12 2004-12-15 Novartis Ag Organic compounds
GB0427604D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
EP1846408B1 (en) 2005-01-14 2013-03-20 Janssen Pharmaceutica NV 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006074984A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as cell cycle kinase inhibitors
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
GB0507575D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
WO2006122230A1 (en) * 2005-05-11 2006-11-16 Array Biopharma Inc. P38 inhibitors and methods of use thereof
KR101011958B1 (ko) 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 ｐ38 ＭＡＰ 키나아제 저해제로서의 융합형 피라졸
BRPI0614884A2 (pt) 2005-08-25 2011-04-19 Hoffmann La Roche inibidores de p38 map cinase e métodos para uso dos mesmos
KR101011956B1 (ko) * 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법
GB0522880D0 (en) * 2005-11-09 2005-12-21 Glaxo Group Ltd Novel compounds
GB0524436D0 (en) * 2005-11-30 2006-01-11 Novartis Ag Organic compounds
WO2007095161A2 (en) * 2006-02-14 2007-08-23 New York University Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
WO2007103308A2 (en) * 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
CN101405283B (zh) 2006-03-30 2014-06-18 泰博特克药品有限公司 Hiv抑制性5-酰氨基取代的嘧啶类化合物
WO2007139778A2 (en) * 2006-05-22 2007-12-06 University Of Virginia Patent Foundation Rhamnose substituents of sl0101 and therapeutic uses thereof
KR20090064602A (ko) * 2006-10-16 2009-06-19 노파르티스 아게 단백질 키나제 억제제로서 유용한 페닐아세트아미드
US8148361B2 (en) 2006-11-10 2012-04-03 Bristol-Myers Squibb Company Kinase inhibitors
EP2091952A1 (en) * 2006-12-19 2009-08-26 F. Hoffmann-Roche AG Pyrazolo ý3, 4 -d¨pyrimidine p38 map kinase inhibitors
WO2009023053A2 (en) * 2007-05-18 2009-02-19 University Of Virginia Patent Foundation Use of rsk inhibitors to impede intracellular pathogen infections
EA019869B1 (ru) * 2007-11-28 2014-06-30 Дана Фарбер Кансер Инститьют, Инк. Низкомолекулярные миристатные ингибиторы тирозинкиназы bcr-abl и способы их применения
US8987280B2 (en) * 2008-01-30 2015-03-24 Genentech, Inc. Pyrazolopyrimidine PI3K inhibitor compounds and methods of use
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
CN104592231A (zh) * 2008-06-10 2015-05-06 Abbvie公司 新的三环化合物
WO2010011620A1 (en) * 2008-07-21 2010-01-28 Wyeth 4-phenoxy-6-aryl-1h-pyrazolo[3,4-d]pyrimidine and n-aryl-6-aryl-1h-pyrazolo[3,4-d]pyrimidin-4-amine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010059788A1 (en) 2008-11-20 2010-05-27 Genentech, Inc. Pyrazolopyridine pi3k inhibitor compounds and methods of use
US8343961B2 (en) 2009-03-31 2013-01-01 Arqule, Inc. Substituted heterocyclic compounds
PH12012501000A1 (en) * 2009-12-01 2013-02-11 Abbvie Inc Novel tricyclic compounds
RU2711869C3 (ru) 2009-12-01 2022-02-02 Эббви Инк. Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
WO2011156698A2 (en) * 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
BR112013011520A2 (pt) * 2010-11-19 2019-09-24 Hoffmann La Roche pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
TWI399205B (zh) * 2011-01-14 2013-06-21 Univ Kaohsiung Medical 茶鹼化合物之抑制骨質疏鬆症活性
EP2548878A1 (en) * 2011-07-21 2013-01-23 Laboratorios Del. Dr. Esteve, S.A. Pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma ligands
CN102746306B (zh) * 2012-07-09 2014-11-19 四川国康药业有限公司 别嘌醇类衍生物及其制备方法和用途
CN103570723B (zh) * 2012-07-27 2016-07-13 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
AU2013343105B2 (en) 2012-11-08 2016-04-14 Pfizer Inc. Heteroaromatic compounds as dopamine D1 ligands
CN103601722B (zh) * 2013-09-13 2016-03-02 南京华威医药科技开发有限公司 新型抗肿瘤化合物
SG11201607586UA (en) 2014-03-13 2016-10-28 Agency Science Tech & Res Fused pyrimidine-based hydroxamate derivatives
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
WO2018081451A1 (en) 2016-10-26 2018-05-03 Indiana University Research And Technology Corporation Small molecule protein arginine methyltransferase 5 (prmt5) inhibitors and methods of treatment
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
MX2024007009A (es) * 2021-12-08 2024-08-22 Kineta Inc Heteroarenos bicíclicos y métodos para su uso.
CN117865965B (zh) * 2024-01-08 2024-06-28 贵州省天然产物研究中心 吡咯并嘧啶-4-胺和吡唑并嘧啶-4-胺衍生物及制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720674A (en) * 1970-09-02 1973-03-13 Squibb & Sons Inc 4-amino-1h-pyrazolo(3,4-d)pyrimidine derivatives
GB1544419A (en) * 1975-11-19 1979-04-19 Science Union & Cie Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5723608A (en) * 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
DK1017378T3 (da) 1997-09-23 2003-03-17 Astrazeneca Ab Amidderivater til behandling af sygdomme medieret af cytokiner
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
JP4649046B2 (ja) 1999-05-21 2011-03-09 ブリストル−マイヤーズ スクイブ カンパニー キナーゼのピロロトリアジン阻害剤
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
US6548509B2 (en) * 1999-10-22 2003-04-15 Neurogen Corporation 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
ES2237470T3 (es) 1999-11-10 2005-08-01 Ortho-Mcneil Pharmaceutical, Inc. 2-aril-3-(heteroaril)-imidazo(1,2-alfa)pirimidinas sustituidas; y composiciones farmaceuticas y procedimientos asociados.
AU2001277621A1 (en) 2000-08-09 2002-03-04 Astrazeneca Ab Antiangiogenic bicyclic derivatives
WO2002012226A1 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Quinoline derivatives having vegf inhibiting activity
WO2002012228A1 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Cinnoline compounds
WO2002012227A2 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Indole, azaindole and indazole derivatives having vegf inhibiting activity
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TW200306841A (en) 2002-04-23 2003-12-01 Bristol Myers Squibb Co Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
PT1497019E (pt) 2002-04-23 2015-09-10 Bristol Myers Squibb Co Compostos de pirrolotriazina anilina úteis como inibidores de quinase

Similar Documents

Publication Publication Date Title
JP2005531584A5 (https=)
JP2005523338A5 (https=)
JP2005529890A5 (https=)
CN100415724C (zh) 嘧啶衍生物
JP2023106403A5 (https=)
JP2005511722A5 (https=)
CY2014032I2 (el) Νεα φαρμακα για τη θεραπεια της χρονιας αποφρακτικης πνευμονοπαθειας
JP2006510676A5 (https=)
JP2008508303A5 (https=)
DK1462100T3 (da) Præparat, der omfatter formoterol og et glucocorticosteroid
JP2007514637A5 (https=)
NO20061254L (no) Farmasoytiske blandinger
IL161867A (en) History of 8-pyrazole-xanthine, a process for making them and pharmaceutical preparations containing them
NO20070994L (no) N-hydroksamid derivater og anvendelse derav
WO2001098291A3 (en) 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
YU63003A (sh) Acilirani indanilamini i njihova upotreba kao farmaceutika
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
JP2011522897A5 (https=)
JP2009532417A5 (https=)
ATE419252T1 (de) Antagonisten des a2b-adenosinrezeptors
RU2005106356A (ru) Новое соединение
JP2008513510A5 (https=)
RU2005106355A (ru) Новое соединение
SE9900833D0 (sv) Novel combination
JP2004527489A5 (https=)